Notification That Quarterly Report Will Be Submitted Late (nt 10-q)
May 15 2017 - 3:31PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 12b-25
NOTIFICATION OF LATE FILING
Commission File Number
000-22179
(Check One):
[ ] Form 10-K [ ] Form
20-F [ ] Form 11-K [X] Form 10-Q [ ] Form 10D
[ ] Form N-SAR [ ] Form N-CSR
For Period Ended:
March 31,
2017
[ ]
|
|
Transition Report on Form 10-K
|
[ ]
|
|
Transition Report on Form 20-F
|
[ ]
|
|
Transition Report on Form 11-K
|
[ ]
|
|
Transition Report on Form 10-Q
|
[ ]
|
|
Transition Report on Form N-SAR
|
For the Transition Period Ended: ___________________
Nothing in this form shall be construed to
imply that the Commission has verified any information contained herein.
If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates: _______________________________________________
|
PART I
REGISTRANT INFORMATION
Full Name of Registrant:
Guided
Therapeutics, Inc.
Address of Principal Executive
Office
(Street and number)
:
5835 Peachtree Corners East, Suite D
City, State and Zip Code:
Norcross, Georgia 30092
PART II
RULES 12b-25(b) AND (c)
If
the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule
12b-25(b), the following should be completed. (Check box if appropriate)
|
(a) The reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;
|
[X]
|
(b) The subject annual report, semi-annual report, transition report on Form 10-K, Form
20-F, 11-K, Form N-SAR, or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following
the prescribed due date; or the subject quarterly report or transition report on Form 10-Q, or portion thereof will be
filed on or before the fifth calendar day following the prescribed due date; and
|
|
(c) The accountant's statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.
|
PART III
NARRATIVE
State below in reasonable detail the
reasons why Forms 10-K, 20-F, 11-K, 10-Q, N-SAR, N-CSR or the transition report or portion thereof, could not be filed within the
prescribed time period.
The
registrant’s quarterly report on Form 10-Q could not be filed within the prescribed time period. During the first quarter
of 2017, the registrant continued to experience considerable financial constraints. These financial constraints have postponed
the ability of the registrant’s auditors from reviewing the Form 10-Q and in starting the Financial review process and thus
resulted in delays in the preparation and presentation of financial information. These delays contributed to the registrant’s
inability to process and review the financial information required to file the quarterly report on Form 10-Q by the date required
without incurring undue hardship and expense.
The
registrant expects to file its Form 10-Q within the permitted extension period.
PART IV
OTHER INFORMATION
(1)
Name and telephone number of person to contact in regard to this notification
|
|
Gene S. Cartwright
|
|
(770)
|
|
242-8723
|
(Name)
|
|
(Area Code)
|
|
(Telephone Number)
|
|
|
|
|
|
|
(2)
Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the
Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file
such report(s) been filed? If answer is no, identify report(s).
Yes
[X ] No [ ]
(3)
Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year
will be reflected by the earnings statements to be included in the subject report or portion thereof?
Yes
[ ] No [X ]
If
so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons
why a reasonable estimate of the results cannot be made.
Guided Therapeutics,
Inc.
(Name
of Registrant as Specified in Charter)
has caused this notification to be signed on its behalf by
the undersigned thereunto duly authorized.
|
|
Date: May 15, 2017
|
By:
/s/ Gene S. Cartwright
|
|
Gene S. Cartwright
President and Chief Executive
Officer
|
Guided Therapeutics (QB) (USOTC:GTHP)
Historical Stock Chart
From Aug 2024 to Sep 2024
Guided Therapeutics (QB) (USOTC:GTHP)
Historical Stock Chart
From Sep 2023 to Sep 2024